Olumiant® showed significant improvements in the severity and extent of atopic dermatitis and other patient-reported outcomes in Phase 3 study analyses
Share: Extended safety analysis across eight studies helps further define the known safety profile of Olumiant 2-mg in atopic dermatitis TORONTO, April 30, 2021 /CNW/ - Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company and Incyte's Olumiant® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate- to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis,...
Source: benzinga.com
